Metformin-Driven Activation of Polymorphic Follicle-Stimulating Hormone Receptors for Polycystic Ovary Syndrome Treatment: A Computational Study
Abstract
BACKGROUND Polycystic ovarian syndrome (PCOS) is characterized by anovulation, hyperandrogenism, and, predominantly, insulin resistance. Such characteristics are often associated with disrupted follicle-stimulating hormone receptor (FSHR) function. Conventionally, metformin is commonly used to enhance insulin sensitivity, reduce androgen levels, and indirectly restore FSHR signalling. However, to date, there have been no binding studies investigating metformin-induced FSHR activation and its associated genetic polymorphisms in PCOS. MATERIAL AND METHODS The present study used a systematic approach to examine the structural consequences of wild-type and polymorphic variants of FSHR (A307T and N680S, respectively), along with metformin efficacy, through homology modelling, structural stability analysis, molecular docking, and dynamic simulations. RESULTS The three-dimensional structures of wild-type and variant (A307T and N680S, respectively) FSHR were modelled and validated using computational tools. Pathogenicity prediction revealed that these variants impact the structural stability of FSHR. Molecular docking calculations with metformin showed binding affinities for wild-type (-4.205 kcal/mol), A307T (-4.321 kcal/mol), and N680S (-4.294 kcal/mol). Molecular dynamics (MD) simulations revealed that metformin showed more stable confirmation with A307T and N680S variant forms than wild-type FSHR. These findings suggest that PCOS patients with the A307T and N680S polymorphisms…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.